Please wait a minute...
ZJUS-B
Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)  2005, Vol. 6 Issue ( 7): 10-    DOI: 10.1631/jzus.2005.B0664
    
Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance
LI Min-wei, HOU Wei, WO Jian-er, LIU Ke-zhou
Institute of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China
Download:     PDF (0 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Objectives: To investigate the relationship between HBV (hepatitis B virus) polymerase gene 180 and 204 sites mutation and lamivudine resistance. Methods: One hundred forty-one patients with lamivudine resistance after lamivudine treatment and 60 chronic hepatitis B patients without lamivudine treatment were enrolled in this study. The serum HBV DNA mutation was analyzed by sequence detection via polymerase chain reaction (PCR). The sequences of the same patient were analyzed before and after lamivudine treatment. Results: One hundred and nine lamivudine resistance patients had HBV YMDD (tyrosine-methionine-aspartate-aspartate) mutation. Among them, 45 patients had rtL180M/M204V mutation (41.28%), 28 patients had rtL180M/M204I mutation (25.70%) and 36 patients had rtM204I mutation (33.02%). There were 6 patients with rtL180M mutation in 32 lamivudine resistance patients. Sixty chronic hepatitis patients without lamivudine treatment had no mutations. Conclusions: HBV mutations, which play an important role in lamivudine resistance usually locate at polymerase gene 204 site; 180 site mutation was also observed in these patients. Evaluation of the anti-virus therapy by surveillance of the two sites mutations is of importance.

Key words： Hepatitis B virus      Lamivudine      YMDD mutant      Sequence analysis     
Received: 12 November 2004     
CLC:  R512.6+2  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
LI Min-wei
HOU Wei
WO Jian-er
LIU Ke-zhou
Cite this article:

LI Min-wei, HOU Wei, WO Jian-er, LIU Ke-zhou. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2005, 6( 7): 10-.

URL:

http://www.zjujournals.com/xueshu/zjus-b/10.1631/jzus.2005.B0664     OR     http://www.zjujournals.com/xueshu/zjus-b/Y2005/V6/I 7/10

[1] Jing-yao Pang, Kui-jun Zhao, Jia-bo Wang, Zhi-jie Ma, Xiao-he Xiao. Green tea polyphenol, epigallocatechin-3-gallate, possesses the antiviral activity necessary to fight against the hepatitis B virus replication in vitro[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(6): 533-539.
[2] Yong MAO, Xin HUANG, Ke YU, Hai-bin QU, Chang-xiao LIU, Yi-yu CHENG. Metabonomic analysis of hepatitis B virus-induced liver failure: identification of potential diagnostic biomarkers by fuzzy support vector machine[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2008, 9(6): 474-481.
[3] Xing-guo ZHANG, Jing MIAO, Min-wei LI, Sai-ping JIANG, Fu-qiang HU, Yong-zhong DU. Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2008, 9(6): 506-510.
[4] LIU Ke-zhou, HOU Wei, ZUMBIKA Edward, NI Qin. Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2005, 6(12): 8-.
[5] CHEN Zhe, XU Ze-feng, YE Jing-jia, YAO Hang-ping, ZHENG Shu, DING Jia-yi. Combination of small interfering RNAs mediates greater inhibition of human hepatitis B virus replication and antigen expression[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2005, 6( 4): 3-.